% | $
Quotes you view appear here for quick access.

Compugen Ltd. (CGEN) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • unbearibull unbearibull Dec 31, 2009 11:21 AM Flag

    BioWorld article - parts 1 & 2

    Part 2:

    By understanding the underlying science, "you can predict that a molecule should do what you want it to do by predicting the sequence," Gerstel said.

    Compugen has created predictive models, algorithms and other computational biology methodologies that provide the infrastructure for the design of systematic platforms for the predictive discovery of drug, target and biomarker candidates.

    The company, which Gerstel said has validated 10 disclosed product discovery platforms directed at various drug and diagnostic areas, licenses out the therapeutic proteins it identifies for clinical development and commercialization, and gains performance milestones and sales royalties.

    "Milestones and royalties on these things are wonderful, because they are pure profit," he declared.

    However, he added, "it is very difficult to time your company's financial needs" based on milestones and royalties that could come six months earlier or later than expected. On the other hand, research revenues are typically committed to significantly in advance, Gerstel noted.

    "The company now has hopefully built our revenue base largely out of research revenues, so that by the end of 2011, our research revenues will cover the total corporate expenditures, and then when the milestones and royalties come in, they will go right to the bottom line as profit," he said.

    The company's plans are to "break even largely on research revenues," Gerstel said.

    Nonetheless, he added, Compugen should have "meaningful milestones during the next couple of years, in the 2010-2011 time frame."

    Gerstel said his company has no plans to become a drug developer. "We have no expertise beyond the prediction and selection of these product candidates, and I have no interest in creating that type of capability here of taking products further along," he said. "It makes no sense when there are plenty of places out there that could develop drugs and do it much better than we."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
6.81+0.05(+0.74%)Sep 23 4:00 PMEDT